Troponin Mutation Caused Diastolic Dysfunction and Experimental Treatment in Transgenic Mice with Cardiomyopathy
Tóm tắt
Troponin, a contractile protein of the thin filament of striated muscle, consists of three subunits: troponin C (TnC), troponin T (TnT), and troponin I (TnI). Cardiac troponin I (cTnI) plays a critical role in regulation of cardiac function. The physiological effect of cTnI, as an inhibitory subunit of troponin complex, is to prevent the interaction between myosin heavy chain heads and actins, i.e. the cross-bridge formation, and to ensure a proper relaxation of cardiac myofilaments. In pathological conditions, the deficiency of cTnI or mutations in cTnI especially in the C-terminus of cTnI is associated with diastolic dysfunction caused by myofibril hypersensitivity to Ca2+. Our laboratory has generated cTnI knockout mouse model to investigate the cellular and molecular function of cTnI and created cTnI mutant disease mouse models to explore the pathophysiology caused by cTnI mutations in the heart. Here, we present our recent studies on physiological function of cTnI in the heart and the pathological consequences caused by the cTnI mutations in the diseased heart using the transgenic mouse models. The mechanisms underlying diastolic dysfunction and heart failure caused by cTnI mutations are explored in cell-based assays and in transgenic animal models. These studies provide us with useful information in searching for therapeutic strategies and target-oriented medication for the treatment of diastolic dysfunction and heart failure.
Tài liệu tham khảo
J. Wynne, “Restrictive cardiomyopathy,” Curr Treat Options Cardiovasc Med, vol.2, pp.431–438, 2000.
X.P. Huang, Y. Pi, K. Lee, A. Henkel, R. Gregg, P. Powers, J. Walker, “Cardiac troponin I gene knockout, a mouse model of myocardial troponin I deficiency,’ Circ Res, vol. 84, pp1–8, 1999.
J. Du, “C. Zhang, J. Liu, C. Sidky, X.P. Huang, “A point mutation (R192H) in the C-terminus of human cardaic troponin I causes diastolic dysfunction in transgenic mice,” Arch Biochem Biophys, vol. 456, pp.143–150, 2006.
P. Jean-Charles, C. Nan, L. Zhang, J. Tian, X.P. Huang, “Cardiac troponin mutations: Diastolic dysfunction and therapeutic options,” in Troponin, J.-P. Jin Eds. Nova Biomedical, 2014, pp. 259–281.
J. Mogensen, T. Hubo, M. Duque, W. Uribe, A. Shaw, R. Murphy, J.R. Gimeno, P. Elliott, W.J. McKenna, “Idiopathic restrictive cardiomyopathy is part of the clinical expression of cardiac troponin I mutations,” J Clin Invest, vol.111, pp.209–216, 2003.
F. Gambarin, C. Ho, C. Semsarian, M. Baldi, M. Will, K. Baldini, F. Torricelli, L. Teates, F. Cecchi, M. Ackerman, I. Olivotto, “Clinical features and outcome of hypertrophic cardiomyopathy assocaited with triple sarcomere protein gene mutations. J Am Coll Cardiol, vol.55, pp.1444–1453, 2010.
S. Yang, M. Hitz, G. Andelfinger, “Ventricular septal defect and restrictive cardiomyopathy in a pediatric TNNI3 mutationcarrier, Cardiol Young, vol.20, pp.574–576, 2001.
Y. Li, L. Zhang, P. Jean-Charles, C. Nan, G. Chen, J. Tian, J.-P. Jin, I. Gelb, X.P. Huang, “Dose-dependent diastolic dysfunction and early death in a mouse model with cardiac troponin mutations,” J Mol Cell Cardiology, vol.62, pp.227–236, 2013.
J. Du, J. Liu, H.Z. Feng, M.M. Houssain, N. Gobara, C. Zhang, Y. Li, P. Jean-Charles, J.P. Jin, X.P. Huang, “Impaired relaxation is the main manifestation in transgenic mice expressing a restrictive cardiomyopahty mutation, R193H, in cardiac TnI,” Am J Physiol Heart Circ Physiol, vol.294, pp.:H2604-H2613, 2008.
Y. Li, P. Jean-Charles, C. Nan, J. Pinto, Y. Wang, J Liang, G. Wu, J. Tian, H. Feng, J. Potter, J.-P. Jin, X.P. Huang, “Correcting diastolic dysfunction by Ca2+ desensitizing troponin in a transgenic mouse model of restrictive cardiomyopathy,” J Cell Mol Cardiol, vol. 49, pp.402–411, 2010.
J. Liu, J. Du, C. Zhang, J.W. Walker, X.P. Huang, “Progressive troponin I loss impaires cardiac relaxation and causes heart failure in mice,” Am J Physiol Heart Circ Physiol, vol.293, pp.H1273-H1281, 2007.
S. Akhter, K. Bueltmann, Jr., X.P. Huang and J.-P. Jin , “Restrictive cardiomyopathy mutations demonstrate functional importance of the C-terminal end segment of troponin I,” Arch Biochem Biophys, 2013, doi:http://dx.doi.org/10.1016/j.abb.2013.12.001.
Z. Yu, L. Zhang, J.-P. Jin, “A proteolytic NH2-terminal truncation of cardiac troponin I that is up-regulated in simulated microgravity, J Biol Chem, vol.276, pp.15753–15760, 2001.
Y. Liou, S. Kuo, S. Hsieh, "Differential effects of a green tea-derived polyphenol (-)-epigallocatechin-3-gallate on the acidosis-induced decrease in the Ca(2+) sensitivity of cardiac and skeletal muscle," Pflugers Arch, vol.456, pp.787–800, 2008.
IM. Robertson, MX. Li, BD. Sykes, “Solution structure of human cardiac troponin C in complex with the green tea polyphenol, (-)-epigallocatechin 3-gallate,” J Biol Chem, vol.284, pp.23012–23023, 2009.